Ihuman Net Worth
Ihuman Net Worth Breakdown | IH |
Ihuman Net Worth Analysis
Ihuman's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ihuman's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ihuman's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ihuman's net worth analysis. One common approach is to calculate Ihuman's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ihuman's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ihuman's net worth. This approach calculates the present value of Ihuman's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ihuman's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ihuman's net worth. This involves comparing Ihuman's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ihuman's net worth relative to its peers.
Enterprise Value |
|
To determine if Ihuman is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ihuman's net worth research are outlined below:
| Ihuman Inc appears to be risky and price may revert if volatility continues | |
| Ihuman Inc has a strong financial position based on the latest SEC filings | |
| Latest headline from news.google.com: Short Interest in iHuman Inc. Decreases By 60.3 percent - MarketBeat |
Ihuman uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ihuman Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ihuman's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Ihuman Target Price Consensus
Ihuman target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Ihuman's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Ihuman analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Ihuman stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Ihuman Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationIhuman Target Price Projection
Ihuman's current and average target prices are 3.18 and 3.78, respectively. The current price of Ihuman is the price at which Ihuman Inc is currently trading. On the other hand, Ihuman's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Ihuman Target Price
Know Ihuman's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ihuman is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ihuman Inc backward and forwards among themselves. Ihuman's institutional investor refers to the entity that pools money to purchase Ihuman's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-12-31 | 47.7 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 41.8 K | Rhumbline Advisers | 2024-12-31 | 11.4 K | Crédit Agricole S.a. | 2024-12-31 | 10 K | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 3.5 K | Ubs Group Ag | 2024-12-31 | 3.3 K | State Street Corp | 2024-09-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-12-31 | 0.0 |
Follow Ihuman's market capitalization trends
The company currently falls under 'Small-Cap' category with a market capitalization of 162.93 M.Market Cap |
|
Project Ihuman's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.11 | 0.12 | |
| Return On Capital Employed | 0.19 | 0.18 | |
| Return On Assets | 0.11 | 0.12 | |
| Return On Equity | 0.22 | 0.21 |
When accessing Ihuman's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ihuman's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ihuman's profitability and make more informed investment decisions.
Evaluate Ihuman's management efficiency
Ihuman Inc has Return on Asset (ROA) of 0.0348 % which means that for every $100 of assets, it generated a profit of $0.0348. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1136 %, which means that it produced $0.1136 on every 100 dollars invested by current stockholders. Ihuman's management efficiency ratios could be used to measure how well Ihuman manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Ihuman's Return On Tangible Assets are increasing as compared to previous years. The Ihuman's current Return On Assets is estimated to increase to 0.12, while Return On Capital Employed is projected to decrease to 0.18. As of now, Ihuman's Return On Assets are increasing as compared to previous years. The Ihuman's current Asset Turnover is estimated to increase to 1.17, while Total Assets are projected to decrease to under 945.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.14 | 3.30 | |
| Tangible Book Value Per Share | 3.07 | 3.22 | |
| Enterprise Value Over EBITDA | 25.59 | 26.87 | |
| Price Book Value Ratio | 1.14 | 1.20 | |
| Enterprise Value Multiple | 0.04 | 0.04 | |
| Price Fair Value | 1.14 | 1.20 | |
| Enterprise Value | 5.6 B | 5.3 B |
Examining the leadership quality of Ihuman Inc offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 0.0141 | Revenue | Quarterly Revenue Growth (0.08) | Revenue Per Share | Return On Equity |
Ihuman Corporate Filings
6K | 26th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify |
Ihuman Earnings per Share Projection vs Actual
Ihuman Corporate Management
| Wendy Hayes | Independent Director | Profile | |
| Yufeng Chi | Chairman of the Board | Profile | |
| Xuenan Li | Independent Director | Profile | |
| Hanfeng Chi | Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ihuman Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Hotels, Restaurants & Leisure space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ihuman. If investors know Ihuman will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ihuman listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.53) | Earnings Share 0.27 | Revenue Per Share | Quarterly Revenue Growth (0.08) | Return On Assets |
The market value of Ihuman Inc is measured differently than its book value, which is the value of Ihuman that is recorded on the company's balance sheet. Investors also form their own opinion of Ihuman's value that differs from its market value or its book value, called intrinsic value, which is Ihuman's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ihuman's market value can be influenced by many factors that don't directly affect Ihuman's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ihuman's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ihuman is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ihuman's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.